Inhibitor Loxo-292 CAS 2152628-33-4 Selitrectinib

• Customization: Available
• Powder: Yes
• Customized: Ready to Ship
• Model NO.: jf02-1
• Certification: GMP, ISO 9001, USP
• Suitable for: Elderly, Adult
• State: Solid
• Purity: >99%
• Sample: Free
• Application: for Antibacteria
• Impurity: 0.01%
• Assay: 99.5%
• Residual Solvent: Ethanol
• Annul Sales: 2000kg
• Heavy Metal: 10ppm
• Capacity: 2500kg
• Stock: 2.00kg
• Water: 0.01%
• Market: India
• Ever Exported?: Yes
• Brand: Eliquis
• Volume: 200kg
• Experience: 10years
• Transport Package: Air
• Specification: JP
• Trademark: jianfeng
• Origin: Shandong
• HS Code: 2804898888
• Production Capacity: 500kg

Product Description

Product Description

Inhibitor LOXO-292 cas 2152628-33-4

Larotrectinib (Loxo-101) CAS No. 1223405-08-0
Selpercatinib (LOXO-292) showed promising activity in RET-mutant MTC and RET fusion-positive thyroid cancer
Background: Selpercatinib (LOXO-292) is a highly selective and potent small molecule RET kinase inhibitor. Here we report an update on the efficacy and safety of selpercatinib in RET-fusion+ non-small-cell lung cancer (NSCLC).
Selpercatinib (LOXO-292) was well tolerated in a large safety data set
The safety data set included all 531 patients with various cancer types that were treated.  Five treatment-emergent adverse events occurred in ≥15% of patients, including dry mouth, diarrhoea, hypertension, increased ALT, and increased AST. The adverse events were mostly grades 1 and 2. Treatment discontinuation due to a treatment-related adverse event occurred in nine patients (1.7%).